- Home
- CRMD
CRMD
CorMedix Inc.
as 08-01-2025 4:00pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 877.5M | IPO Year: | 2010 |
| Target Price: | $17.33 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $17.43 | Next Earning Date: | 08-13-2025 |
| Revenue: | $82,553,827 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 278.96% | Revenue Growth (next year): | 45.85% |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Barchart
a month ago
S&P 500 and Nasdaq Climb to Record Highs on China Trade Optimism
Simply Wall St.
a month ago
Upgrade: Analysts Just Made A Captivating Increase To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Barchart
a month ago
S&P 500 and Nasdaq 100 Post Record Highs on Hopes of Trade Deals
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT Newswires
a month ago
CorMedix Prices $85 Million Offering; Shares Fall Pre-Bell
GlobeNewswire
a month ago
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
MT Newswires
a month ago
CorMedix Plans $85 Million Stock Sale
GlobeNewswire
a month ago
CorMedix Inc. Announces Proposed Public Offering of Common Stock
Compare CRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.